Literature DB >> 12790158

Smoking and tardive dyskinesia: lack of involvement of the CYP1A2 gene.

Siow-Ann Chong1, Ene-Choo Tan, Chay Hoon Tan.   

Abstract

OBJECTIVE: To establish if there is an association between cigarette smoking and tardive dyskinesia (TD) in patients with schizophrenia and to evaluate the role of the CYP1A2 polymorphism in TD in patients of Chinese descent.
METHOD: Two-hundred and ninety-one patients diagnosed with schizophrenia according to DSM-IV criteria were included in the study. Dyskinesia was assessed by the Abnormal Involuntary Movement Scale and TD by the criteria of Schooler and Kane. Demographic and clinical data and information on smoking habits were collected, and patients of Chinese descent with a well established smoking history were subsequently genotyped for CYP1A2.
RESULTS: Forty-three (41.3%) of the 104 patients with a history of smoking and 52 (27.8%) of the 187 non-smokers were diagnosed with TD. The prevalence of TD was significantly higher among smokers than non-smokers (chi2 = 5.57, p = 0.018). Logistic regression using TD as the dependent variable revealed smokers to be at a significantly higher risk for TD (p < 0.005). Genotyping of smokers of Chinese descent for CYP1A2 polymorphism revealed no significant differences in the genotypic or allelic distribution between those with and without TD.
CONCLUSIONS: Consistent with other studies, the prevalence of TD was significantly higher among smokers than non-smokers; however, we did not find an association between the C --> A genetic polymorphism of CYP1A2 and TD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12790158      PMCID: PMC161742     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  30 in total

1.  Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia.

Authors:  R Segman; T Neeman; U Heresco-Levy; B Finkel; L Karagichev; M Schlafman; A Dorevitch; A Yakir; A Lerner; A Shelevoy; B Lerer
Journal:  Mol Psychiatry       Date:  1999-05       Impact factor: 15.992

2.  Prevalence of smoking among psychiatric outpatients.

Authors:  J R Hughes; D K Hatsukami; J E Mitchell; L A Dahlgren
Journal:  Am J Psychiatry       Date:  1986-08       Impact factor: 18.112

3.  Smoking in chronic schizophrenia.

Authors:  A K Gopalaswamy; R Morgan
Journal:  Br J Psychiatry       Date:  1986-10       Impact factor: 9.319

4.  A controlled trial of combined medications on behavioral and extrapyramidal effects.

Authors:  G M Simpson; L Krakov; E Kunz-Bartholini
Journal:  Acta Psychiatr Scand Suppl       Date:  1970

5.  Research diagnoses for tardive dyskinesia.

Authors:  N R Schooler; J M Kane
Journal:  Arch Gen Psychiatry       Date:  1982-04

6.  Effects of single injections of nicotine on the ascending dopamine pathways in the rat. Evidence for increases of dopamine turnover in the mesostriatal and mesolimbic dopamine neurons.

Authors:  K Andersson; K Fuxe; L F Agnati
Journal:  Acta Physiol Scand       Date:  1981-07

7.  Lack of impact of CYP1A2 genetic polymorphism (C/A polymorphism at position 734 in intron 1 and G/A polymorphism at position -2964 in the 5'-flanking region of CYP1A2) on the plasma concentration of haloperidol in smoking male Japanese with schizophrenia.

Authors:  Kazutaka Shimoda; Toshiyuki Someya; Sachiyo Morita; Genta Hirokane; Aya Yokono; Saburo Takahashi; Masako Okawa
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2002-02       Impact factor: 5.067

8.  Neuroleptic and anticholinergic drug use in Chinese patients with schizophrenia resident in a state psychiatric hospital in Singapore.

Authors:  S A Chong; P Sachdev; R Mahendran; H C Chua
Journal:  Aust N Z J Psychiatry       Date:  2000-12       Impact factor: 5.744

9.  Nicotine exposure and tardive dyskinesia.

Authors:  R Yassa; S Lal; A Korpassy; J Ally
Journal:  Biol Psychiatry       Date:  1987-01       Impact factor: 13.382

10.  Smoking and malignancy in schizophrenia.

Authors:  E Masterson; B O'Shea
Journal:  Br J Psychiatry       Date:  1984-10       Impact factor: 9.319

View more
  8 in total

Review 1.  Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.

Authors:  Jian-Ping Zhang; Anil K Malhotra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-01       Impact factor: 4.481

2.  Early nicotine withdrawal and transdermal nicotine effects on neurocognitive performance in schizophrenia.

Authors:  Christopher G AhnAllen; Paul G Nestor; Martha E Shenton; Robert W McCarley; Margaret A Niznikiewicz
Journal:  Schizophr Res       Date:  2007-09-19       Impact factor: 4.939

3.  Cigarette smoking in male patients with chronic schizophrenia in a Chinese population: prevalence and relationship to clinical phenotypes.

Authors:  Xiang Yang Zhang; Jun Liang; Da Chun Chen; Mei Hong Xiu; Jincai He; Wei Cheng; Zhiwei Wu; Fu De Yang; Colin N Haile; Hongqiang Sun; Lin Lu; Therese A Kosten; Thomas R Kosten
Journal:  PLoS One       Date:  2012-02-07       Impact factor: 3.240

Review 4.  Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders.

Authors:  Florence Cf Chang; Victor Sc Fung
Journal:  Pharmgenomics Pers Med       Date:  2014-10-13

5.  Assessment of Extrapyramidal Symptoms Associated with Psychotropics Pharmacological Treatments, and Associated Risk Factors.

Authors:  Dania Abu-Naser; Sara Gharaibeh; Ahmad Z Al Meslamani; Qais Alefan; Renad Abunaser
Journal:  Clin Pract Epidemiol Ment Health       Date:  2021-02-16

Review 6.  Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies.

Authors:  Evangelia Eirini Tsermpini; Sara Redenšek; Vita Dolžan
Journal:  Front Pharmacol       Date:  2022-01-24       Impact factor: 5.810

7.  Tardive and spontaneous dyskinesia incidence in the general population.

Authors:  Ray M Merrill; Joseph L Lyon; Paul M Matiaco
Journal:  BMC Psychiatry       Date:  2013-05-28       Impact factor: 3.630

Review 8.  Genetic Testing for Antipsychotic Pharmacotherapy: Bench to Bedside.

Authors:  Mujeeb U Shad
Journal:  Behav Sci (Basel)       Date:  2021-06-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.